NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for rare and complex central nervous system (CNS) disorders. Headquartered in Zurich, Switzerland, the company leverages advanced scientific platforms, including its proprietary dual orexin receptor agonist (DOXA) technology, to target neurobehavioral and neurocognitive challenges such as narcolepsy, ADHD, and other sleep-related conditions. NLS Pharmaceutics is committed to delivering safer, more effective treatments that address significant unmet medical needs in the global CNS therapeutics market. Its pipeline includes lead candidates like Mazindol ER, designed to improve symptoms in patients with narcolepsy and ADHD, as well as other investigational assets targeting neurodegenerative diseases. The company’s research is supported by a network of world-class partners and scientists, emphasizing rigorous clinical development and robust intellectual property. In October 2025, NLS Pharmaceutics completed a strategic merger with Kadimastem Ltd., forming NewcelX Ltd., which consolidates expertise in both drug development and cell therapy to broaden its impact across neurodegenerative diseases and diabetes. This evolution positions the company at the forefront of next-generation CNS therapies, combining cutting-edge science with a patient-centric approach to drive meaningful advances in brain health.